MIN/Sp/AU/CAMH3/6 TB
Page 23
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Namibia
Niger
Nigeria
Rwanda
Sao Tome &
Principe
Senegal
Seychelles
Sierra Leone
South Africa
Swaziland
Togo
Uganda
UR Tanzania
Zambia
Zimbabwe
19475
27,610
4877
2218
127
33,718
15894
8224
66,848
7,680
22,517
27,011
5224
2766
115
35632
15,771
8755
74,225
8,283
9
44.3
0
0.5
90.6
0
16
0
10.3
65.1
0
63.9
9.2
0
87
24.2
0
0
10.1
76.1
0.9
69
18
45.5
142
10120
14
6,930
302,467
8,864
2636
41,809
64,200
53,267
54891
153
100
8208
341,165
9195
2924
41,579
62,100
51,179
47774
100
0
0
0
22.5
0
0
25.2
2.5
2
0
AFR
1,254,751
1 310 841
11.2
22
0
1.7
69.9
14.6
5
70.4
57.5
0
91.7
100
20.7
40.7
0
42.8
0
15.3
3.5
2
0
51.9
8.5
52.8
79.9
71.3
52.1
56.7
52
93.2
0
80
17.4
0
30.8
0
0
0
100
100
100
97.9
87.9
33
0
40.1
19.4
58.9
50.5
62.2
25.1
61.1
0
23.2
56.9
30.6
10.1
22.4
68.1
7.9
25.9
37.9
52.3
72.2
89.1
27.3
37.1
By country, only Comoros and Sao Tome and Principe had achieved the
target in both years. Cape Verde and Mauritius consistently tested over 80%
of notified cases and should easily reach the set target by 2010. Benin,
Botswana, Ethiopia, Kenya, Malawi and Rwanda are also making sufficient
progress from year to year to reach the target by 2010.
Access to essential anti-TB medicines
Uninterrupted supply of first line anti-TB medicines is a basic requirement for
effective DOTS based TB Control Programmes. With the set up of the Global
Drug Facility (GDF) for access to free quality anti-TB first line drugs to all
DOTS based programmes with a GNP of less than 3,000 USD, the availability
of first line anti-TB drugs has improved tremendously. By the end of
December 2007, all 36 eligible countries from the region that applied to the
GDF secured 3 year first line anti-TB drug grants, including pediatric
formulations for some countries.
Notwithstanding, latest available information 33 indicates that only 69% of 42
countries that submitted reports had uninterrupted supply of first line anti-TB
drugs at both the central and peripheral levels during 2006, while 92.8% had
uninterrupted supply at peripheral level. Since implementation is mostly at
peripheral level, approximately 7.2% of countries ran out of drugs at some
point, thereby limiting access to these. This is a significant short fall with
regard to Universal Access to essential TB treatment.
33
WHO Global TB Report 2008
80
45.9
0
43.9
Based on these figures, the proportion of TB cases tested for HIV had
doubled between 2005 and 2006 but falls far below the Universal Access
target of 100%.
4.3:
50
56.9
0
0
34.2
0
12.8
100
15
32.3
20.1
0
26
11.5
22.6
0
0
49.2